Protagenic Therapeutics Valuation
| PTIXW Stock | USD 0 0.00 0.00% |
Protagenic Therapeutics seems to be undervalued based on Macroaxis valuation methodology. Our model determines the value of Protagenic Therapeutics from analyzing the company fundamentals such as Cash Per Share of 0.06 X, return on equity of -2.32, and Net Income of (5 M) as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Protagenic Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Protagenic Therapeutics is based on 3 months time horizon. Increasing Protagenic Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Protagenic stock is determined by what a typical buyer is willing to pay for full or partial control of Protagenic Therapeutics. Since Protagenic Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Protagenic Stock. However, Protagenic Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0034 | Real 0.00454 | Hype 0.003616 |
The intrinsic value of Protagenic Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Protagenic Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Protagenic Therapeutics helps investors to forecast how Protagenic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Protagenic Therapeutics more accurately as focusing exclusively on Protagenic Therapeutics' fundamentals will not take into account other important factors: Protagenic Therapeutics Total Value Analysis
Protagenic Therapeutics is at this time anticipated to have takeover price of 0 with market capitalization of 0, debt of 655.25 K, and cash on hands of 671.09 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Protagenic Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 0 | 655.25 K | 671.09 K |
Protagenic Therapeutics Asset Utilization
One of the ways to look at asset utilization of Protagenic is to check how much profit was generated for every dollar of assets it reports. Protagenic Therapeutics holds a negative application of assets of -0.95 pct., losing $0.009491 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Protagenic Therapeutics shows how discouraging it operates for each dollar spent on its assets.Protagenic Therapeutics Profitability Analysis
Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0.About Protagenic Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Protagenic Therapeutics. We calculate exposure to Protagenic Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Protagenic Therapeutics's related companies.Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company was founded in 2016 and is based in New York, New York. Protagenic Therapeutics is traded on NASDAQ Exchange in the United States.
Protagenic Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Protagenic Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.3 M | |
| Shares Float | 5.8 M |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.